NIJMEGEN, Netherlands and BOSTON, September 9, 2025 — Tagworks Pharmaceuticals has initiated the third dose level in its ongoing Phase 1 clinical trial evaluating TGW101, a first-in-class antibody-drug conjugate (ADC) targeting TAG-72, in patients with advanced solid tumors. This progression underscores the therapy’s favorable safety profile and potential to address unmet needs in oncology, particularly for patients with limited treatment options.

Science Significance

TGW101 is an innovative ADC designed to target TAG-72, a non-internalizing tumor-associated glycoprotein overexpressed in various cancers such as colorectal, ovarian, and pancreatic tumors. Using Tagworks’ proprietary Click-to-Release linker chemistry, TGW101 enables highly selective and controlled release of its cytotoxic payload, monomethyl auristatin E (MMAE).

The ASSERT trial demonstrated significant improvements in pruritus, serum bile acid concentrations, and other biomarkers, while minimizing systemic toxicity. By delivering the drug precisely to the tumor site, TGW101 may offer a safer, more effective option compared to conventional treatments that risk damaging healthy tissue.

Regulatory Significance

The ongoing Phase 1 trial is designed to assess the safety, tolerability, and pharmacokinetics of TGW101 in patients with refractory or relapsed tumors. The trial’s dose-escalation design, with up to seven dose levels planned, aims to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). The fact that three dose levels have been safely administered and reviewed by a dedicated Safety Oversight Committee highlights the therapy’s promising clinical profile and supports further evaluation.

Business Significance

Advancing to the third dose level strengthens TGW101’s position as a next-generation oncology candidate. Its Click-to-Release technology offers a differentiated mechanism, allowing for improved drug delivery and efficacy. This innovation could attract strategic partnerships, investors, and global expansion opportunities, positioning Tagworks at the forefront of oncology therapeutics. The ability to selectively target tumors while sparing healthy tissues aligns with industry trends toward personalized medicine and safer cancer treatments.

Patients’ Significance

For patients living with advanced solid tumors, TGW101 provides new hope where conventional therapies have failed. The precision targeting mechanism reduces harmful side effects, enabling patients to continue treatment without compromising their overall health. Access to such therapies can improve treatment adherence, emotional well-being, and quality of life, especially for those undergoing multiple rounds of chemotherapy or facing severe treatment-related complications.

Policy Significance

The trial’s progress highlights the importance of regulatory pathways that encourage innovation while ensuring patient safety. Agencies worldwide are increasingly prioritizing breakthrough therapies for rare and complex diseases. The success of TGW101’s development can influence policy decisions on clinical trial designs, fast-track approvals, and orphan drug incentives, ultimately shaping the future landscape of cancer treatment accessibility.

The initiation of the third dose level in the TGW101 Phase 1 trial represents a significant step forward in oncology research and treatment. With its proprietary Click-to-Release technology, TGW101 offers a targeted, efficient, and potentially safer approach to delivering cytotoxic agents directly to tumor cells. As the trial progresses, researchers remain optimistic that TGW101 will redefine how advanced tumors are treated, improving outcomes for patients and expanding the boundaries of precision medicine in cancer care. This milestone reinforces the importance of continued investment in innovative therapies aimed at addressing the unmet medical needs of patients worldwide.

Source: Tagworks Pharmaceuticals  BV Press Release